DEF 14A: BioLargo Seeks Stockholder Approval for Reverse Stock Split to Pursue Nasdaq Listing

BioLargo is asking stockholders to approve a reverse stock split to meet the minimum bid price requirement for listing on the Nasdaq Capital Market.

Summary

• BioLargo, Inc. is seeking stockholder approval for several proposals at its 2025 Annual Meeting, including the election of directors, an advisory vote on executive compensation, ratification of the independent auditor, and authorization for a reverse stock split.
• The company aims to gain the authority to effect a reverse stock split of its common stock at a ratio between 1-for-4 and 1-for-10.
• The Board of Directors will determine whether to implement the reverse split and its timing.
• The goal of the reverse stock split is to increase the company's stock price to meet the minimum bid price requirement for listing on the Nasdaq Capital Market.
• The Board believes a Nasdaq listing would attract institutional investors, aid in capital-raising efforts, and enhance the company's profile.
• The company had 301,775,373 shares of common stock outstanding as of April 23, 2025.
• The Board has the right to abandon the reverse stock split even if approved by stockholders.
• The company's executive compensation includes salary, stock awards, option awards, and other compensation such as health insurance and car allowances.
• The company's revenue increased from $5,884,000 in 2022 to $17,779,000 in 2024.
• The company's net loss decreased from $5,132,000 in 2022 to $4,347,000 in 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is pursuing a Nasdaq listing and has shown revenue growth and decreasing losses, the need for a reverse stock split indicates underlying challenges with the stock price. The Board's discretion to abandon the split adds uncertainty.

Positives

• The company is actively pursuing a Nasdaq listing, which could increase visibility and attract more investors.
• Revenue has significantly increased from $5,884,000 in 2022 to $17,779,000 in 2024.
• Net losses have decreased from $5,132,000 in 2022 to $4,347,000 in 2024.
• The Board of Directors is composed of experienced individuals with diverse backgrounds.
• The company has established corporate governance practices, including an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee.

Negatives

• The company currently does not meet the minimum bid price requirement for listing on the Nasdaq Capital Market.
• The Board has the right to abandon the reverse stock split even if approved by stockholders, creating uncertainty.
• The company has a history of net losses, although these losses are decreasing.
• The company's stock price may decline after a reverse stock split due to market volatility and investor response.

Risks

• The reverse stock split may not lead to a sustained increase in the trading price of the company's common stock.
• The market price of the company's shares may decline in value after a reverse stock split.
• The company's operating results and general market conditions could negatively impact the stock price.
• The company may not be successful in its application to list on the Nasdaq Capital Market.
• The company's ability to attract institutional investors and raise capital may be hindered if it is not listed on a national exchange.

Future Outlook

The company intends to pursue a listing on the Nasdaq Capital Market, contingent upon stockholder approval of the reverse stock split and a successful listing application.

Management Comments

• The Board believes that a change in listing from the OTCQX to a national exchange such as the Nasdaq Capital Markets would be beneficial to both the Company and its stockholders.
• The Board would take such action only in conjunction with an approved listing application on a national exchange.

Industry Context

Many small-cap companies pursue reverse stock splits to meet the listing requirements of major exchanges like Nasdaq or NYSE, aiming to increase investor confidence and attract institutional investment.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies trading on over-the-counter markets to meet the minimum share price requirements for listing on exchanges like Nasdaq or the NYSE.
• Comparable companies that have recently undertaken reverse stock splits to uplist include those in the biotechnology and technology sectors, where maintaining exchange listing is crucial for investor confidence and access to capital.
• The typical range for reverse stock splits is similar to the 1-for-4 to 1-for-10 range proposed by BioLargo, as this range aims to achieve a share price that meets exchange requirements without excessively reducing the number of outstanding shares.

Related Party Transactions

• Our officers and board members routinely forego cash compensation in lieu of receiving common stock or options to purchase common stock, pursuant to a plan adopted by our board for the payment of outstanding payables.

Stakeholder Impact

• Stockholders may experience a change in the number of shares they own if the reverse stock split is implemented.
• The company's employees may benefit from increased stability and growth opportunities if the Nasdaq listing is successful.
• Potential investors may be more attracted to the company if it is listed on a national exchange.
• The company's suppliers and customers may benefit from the company's increased visibility and financial stability.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 19, 2025.
• If the reverse stock split is approved, the Board will decide whether and when to implement it.
• The company will file a Certificate of Amendment to effect the reverse stock split if the Board decides to proceed.
• The company will pursue a listing application on the Nasdaq Capital Market.

Key Dates

Keywords

reverse stock split, Nasdaq, listing, proxy statement, executive compensation, directors, BioLargo, stockholders, annual meeting, governance